Insider · CIK 0002048403
Artal Participations S.a r.l.
Files at LXRX (LEXICON PHARMACEUTICALS, INC.), CAVA (CAVA GROUP, INC.). First filing Jun 17, 2026, latest Jun 17, 2026.
Artal Participations S.a r.l. files SEC Form 4 as director and 10% owner at CAVA (CAVA GROUP, INC.), and also at LXRX (LEXICON PHARMACEUTICALS, INC.). Since Jun 17, 2026, Artal Participations S.a r.l. has reported 0 open-market buys worth $0 and 1 open-market sell worth $271M, the latest filed on Jun 17, 2026.
A track record needs three past buys with six months of prices behind them; Artal Participations S.a r.l. has 0, so none is measured yet.
The newest scored trade: sold $271M of CAVA on Jun 15, 2026, filed Jun 17, 2026, scored 65 (notable). In the last 12 months: 0 buys worth $0 and 1 sell worth $271M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CAVA: CAVA GROUP, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 65Notable | CAVA GROUP, INC. | $271M 3,000,000 shares | -32% | +105% from low-8% from high |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | CAVA CAVA GROUP, INC. | SOpen-market sale Common Stock | -3,000,000 | $90.30 | $271M | 6,507,990 | Jun 17, 2026 |
| Apr 30, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stockindirect: See Footnotes | +20,421,735 | $0.00 | $0 | 175,156,062 | May 8, 2026 |
| Apr 30, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Series B Convertible Preferred Stockderivativeindirect: See Footnotes | +408,435 | - | - | 408,435 | May 8, 2026 |
| Apr 30, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Series B Convertible Preferred Stockderivativeindirect: See Footnotes | -408,435 | $0.00 | $0 | 0 | May 8, 2026 |
| Feb 17, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Series B Convertible Preferred Stockindirect: See Footnotes | +41,290 | $65.00 | $2.7M | 408,435 | Feb 19, 2026 |
Questions about Artal Participations S.a r.l.
Answered from the filings on this page, as of the latest one.
Is Artal Participations S.a r.l. buying or selling?
In the last 12 months Artal Participations S.a r.l. reported 0 open-market buys worth $0 and 1 open-market sell worth $271M on SEC Form 4; the latest was sold $271M of CAVA on Jun 15, 2026. Grants, option exercises and tax withholding are not counted.
How did Artal Participations S.a r.l.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Artal Participations S.a r.l. has 0.
Where does Artal Participations S.a r.l. file Form 4?
Artal Participations S.a r.l. has filed Form 4 at CAVA (CAVA GROUP, INC.); LXRX (LEXICON PHARMACEUTICALS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.